Brief Summary

A clinical study of propranolol for the treatment of Kaposi Sarcoma in children and adults. This study will be an open-label single armed treatment trial that will test the effectiveness and the safety of treating Kaposi Sarcoma with propranolol.

Conditions

• Kaposi Sarcoma

Intervention / Treatment

• Drug: Propranolol

Primary Outcome Measures

• Objective Response Rate (At one year)
  ORR is defined as the proportion of participants with complete response (CR), or partial response (PR) based on AIDS Malignancy Consortium Kaposi Sarcoma (AMC KS) Response Criteria.

Countries

Argentina, Brazil, Mexico, Uganda, Zimbabwe

Locations and Investigators

• Fundación Huésped, Buenos Aires, Argentina (Recruiting)
  • Maria Jose Rolon, MD
• Instituto Nacional de Câncer José de Alencar, Rio de Janeiro, Brazil (Not yet recruiting)
  • Fabio Leal, MD, PhD
• Complexo Hospitalar Universitário Professor Edgard Santos, Salvador, Brazil (Not yet recruiting)
  • Carlos Brites, PhD
• Instituto Nacional de Cancerologia, Mexico City, Mexico (Not yet recruiting)
  • Patricia Volkow, MD
  • Patricia Volkow, MD (Principal Investigator)
• Uganda Cancer Institute, Kampala, Uganda (Not yet recruiting)
  • Jackson Orem, MD
  • Jackson Orem, MD (Principal Investigator)
• University of Zimbabwe College of Health Sciences, Harare, Zimbabwe (Not yet recruiting)
  • Margaret Borok, MBChB, FRCP
  • Margaret Borok, MBChB (Hons) FRCP(UK) (Principal Investigator)

Study Officials

• Shane McAllister, Md, PhD (Study Chair) — University of Minnesota Medical School Department of Pediatrics